Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model

NORIHIKO SUGISAWA, KAZUYUKI HAMADA, QINGHONG HAN, JUN YAMAMOTO, YU SUN, HIROTO NISHINO, KEI KAWAGUCHI, MICHAEL BOUVET, MICHIAKI UNNO and ROBERT M. HOFFMAN
Anticancer Research September 2020, 40 (9) 4869-4874; DOI: https://doi.org/10.21873/anticanres.14489
NORIHIKO SUGISAWA
1AntiCancer, Inc., San Diego, CA, U.S.A.
2Department of Surgery, University of California, San Diego, CA, U.S.A.
3Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUYUKI HAMADA
1AntiCancer, Inc., San Diego, CA, U.S.A.
2Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
QINGHONG HAN
1AntiCancer, Inc., San Diego, CA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUN YAMAMOTO
1AntiCancer, Inc., San Diego, CA, U.S.A.
2Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU SUN
1AntiCancer, Inc., San Diego, CA, U.S.A.
2Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROTO NISHINO
1AntiCancer, Inc., San Diego, CA, U.S.A.
2Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEI KAWAGUCHI
3Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL BOUVET
2Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHIAKI UNNO
3Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: all@anticancer.com m_unno@surg.med.tohoku.ac.jp
ROBERT M. HOFFMAN
1AntiCancer, Inc., San Diego, CA, U.S.A.
2Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: all@anticancer.com m_unno@surg.med.tohoku.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: In the present study, we evaluated the efficacy of adjuvant administration of oral recombinant methioninase (o-rMETase) against recurrence and metastasis in a 4T1 murine breast-cancer syngeneic model. Materials and Methods: 4T1 cells were orthotopically implanted into the 2nd mammary fat pad of BALB/c mice. The 4T1 orthotopic syngeneic models were randomized into 2 groups after primary tumor resection: untreated control and o-rMETase (100 units, oral, daily, 2 weeks). Results: The frequency and extent of local recurrence were reduced by o-rMETase. The number of individual cancer cells and metastatic nodules on the lung surface was significantly lower in the o-rMETase-treated mice than the untreated control mice. Conclusion: Adjuvant o-rMETase inhibited local recurrence and lung metastasis after primary tumor resection.

  • Breast cancer
  • surgical resection
  • recurrence
  • methionine restriction
  • recombinant methioninase
  • lung metastasis
  • inhibition
  • adjuvant therapy

Methionine addiction is possibly the most fundamental and general hallmark of cancer (1-9) and is tightly linked to other hallmarks of cancer (2). Methionine addiction was discovered in our laboratory and is due to increased rates of transmethylation compared to normal cells (3-6). Methionine overuse by cancer cells is called the “Hoffman effect”, analogous to the “Warburg effect” of glucose overuse by cancer cells (7). Methionine restriction targets the methionine addiction of cancer. For methionine restriction, we have used L-methionine-deamino-mercapto-methane-lyase (methioninase) (8, 9). Recombinant methioninase (rMETase) has been produced in Escherichia coli containing the methioninase gene cloned from Pseudomonas putida (9). We have reported the efficacy of oral administration of rMETase (o-rMETase) on various types of tumors in vivo, including patient-derived orthotopic xenograft (PDOX) mouse models (10-16).

Breast cancer needs follow-up for long periods after treatment. Although distant recurrence can be detected mostly in the first 5 years, there is still a significant rate of recurrence in the second and the third 5-year periods (17, 18). In order to reduce recurrence and improve survival, systemic adjuvant therapy is administered as the standard of care. Adjuvant endocrine therapy for at least 5 years is recommended for patients with hormone receptor-positive breast cancer (19, 20). Oral endocrine therapy is tolerable long term. However, patients with hormone receptor-negative breast cancer are recommended to take one regimen of adjuvant chemotherapy after surgery and be frequently followed-up for over 5-years. If a novel treatment, tolerable for 5 years, decreases the recurrence rate, it would be recommended for patients with hormone receptor-negative breast cancer.

Murine breast cancer cell lines have been used to generate orthotopic syngeneic models (21-25), especially the 4T1 cell line which has the characteristics of human triple-negative breast cancer (TNBC) and is highly metastatic (21-24). Additionally, the lung is the most frequent site for metastasis in 4T1 orthotopic models. In the present study, we evaluated the efficacy of adjuvant o-rMETase on local recurrence and metastasis after primary-tumor resection in a 4T1 murine breast-cancer orthotopic syngeneic model.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Treatment protocol. The mice were randomized into 2 groups of 3 mice each.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Efficacy of treatment on local recurrence on day 22. (A) Frequency of local recurrence in each group. (B) Bar graphs show weight of local recurrent tumor. Error bars:±SD.

Materials and Methods

Mice. BALB/c mice (AntiCancer, Inc., San Diego, CA, USA) were used in this study. Animal housing and their diet were as previously described (26). Mice were observed on a daily basis and humanely sacrificed by CO2 inhalation if they met the humane endpoint criteria as previously described (26). The protocol was approved by an AntiCancer Inc. Institutional Animal Care and Use Committee (IACUC). All mice were handled according to the principles and procedures provided in the National Institutes of Health Guide for the Care and Use of Animals under Assurance Number A3873-1.

Orthotopic implantation of 4T1 cells. The 4T1 murine breast cancer cell line was obtained from the American Type Culture Collection (Rockville, MD, USA). The cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, and 1% penicillin-streptomycin at 37°C in a 5% CO2 incubator. 4T1 cells (1×106) in phosphate-buffered saline were implanted into the 2nd mammary fat pad of 6-week old BALB/c mice.

Resection of primary tumor. Primary tumor was resected under anesthesia 2 weeks after implantation. The main drainage vein flowing into the subclavian vein was ligated with a 7-0 polypropylene suture (AD Surgical, Sunnyvale, CA, USA) in order to avoid fatal bleeding. The wound was closed with a 6-0 nylon suture (AD Surgical) after confirming hemostasis.

rMETase production. The methioninase gene was originally cloned from Pseudomonas putida and inserted in Escherichia coli, which was used to produce rMETase as previously described (9). rMETase was dissolved in PBS for oral gavage at 500 units/ml.

Treatment of the 4T1 murine breast cancer model. The 4T1-bearing mice were randomized into 2 groups of 3 mice each after primary tumor resection at 2 weeks after tumor implantation (Figure 1): G1: untreated control; G2: oral rMETase (o-rMETase) (100 units, oral, daily, 2 weeks). Mouse body weight was measured twice a week. After 3 weeks, local recurrence was determined and the number of metastatic nodules on the lung surface was macroscopically counted.

Histological examination. Local recurrent primary tumors and metastatic lungs were fixed in 10% formalin. These tissue samples were embedded in paraffin, and then hematoxylin and eosin (H&E) staining was performed according to standard protocol. The H&E-stained slides were observed with a model BH2 microscope (Olympus Corp., Tokyo, Japan).

Statistical analysis. The data are presented as the mean±SD, and the Student's t-test was performed to evaluate the differences between the means. p<0.05 was considered to be statistically significant. Statistical analyses were conducted with GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA, USA).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Efficacy of treatment against post-resection lung metastasis on day 22. (A) Representative photos of resected lungs from each group. Metastatic nodules are shown in white dotted circles. Scale bars: 5 mm. (B) Representative images of histology with H&E staining of the lung of each group. Dotted line shows the margins of a metastatic nodule. Thick arrow indicates extensive cancer cells in the lung of an untreated control mouse. Small black arrows show individual cancer cells in the lung of the o-rMETase-treated mouse. Scale bars: 100 μm. (C) Frequency of lung metastasis in each group. (D) Bar graphs show the number of the nodules on the lung surface in each group. Error bars:±SD. *p<0.05.

Results

Efficacy of treatment on local recurrence. Although all three mice in the untreated control had local recurrence by day 22, only one mouse treated with o-rMETase for 2 weeks had local recurrence (Figure 2A). The weight of the local recurrent tumor tended to be less in the o-rMETase-treated mice [0.24 g±0.42 (mean±SD)] than in the untreated control [0.74 g±1.01 (mean±SD)] (p=0.47) (Figure 2B).

Efficacy of treatment on lung metastasis. Figure 3A shows representative photos of the lungs in each group. Figure 3B shows representative images of H&E-stained histological slides of the lungs in each group. In the untreated control, numerous cancer cells infiltrated into the pulmonary wall, which was replaced with cancer cells and became thickened, and subsequently metastatic nodules arose. In contrast, much fewer cancer cells infiltrated into the pulmonary wall in the o-rMETase-treated mice which had a much milder effect with only slight pulmonary-wall thickening. Lung metastasis was macroscopically detected on day 22 in all three mice in the untreated control and in 2 of 3 (66.7%) mice in the o-rMETase-treated group (Figure 3C). However, the number of metastatic nodules on the lung surface in o-rMETase-treated mice [1.3±2.3 (mean±SD)] was significantly lower than that in the untreated control (5.3±1.5 (mean±SD)) (p=0.032) (Figure 3D).

Effect of treatment on body weight. All mice completed the treatment as scheduled, and there was no mortality. There was no significant difference in relative body weight on day 22 between the untreated control [1.13±0.02 (mean±SD)] and the o-rMETase-treated group [1.19±0.12 (mean±SD)] (p=0.46) (Figure 4).

Discussion

In the present study, adjuvant o-rMETase significantly reduced the number of metastatic nodules on the lung surface of BALB/c mice, which were observed 22 days after surgical resection at the primary tumor. Histological examination showed that metastases occurred in both the untreated-control mice and o-rMETase-treated mice. However, a higher number of cancer cells infiltrated into the lung in the untreated control, and significantly more tumor nodules were observed in the lungs of the untreated-control mice than in the o-rMETase-treated mice. In addition, all 3 mice in the untreated control had local recurrence, while only one mouse treated with o-rMETase had local recurrence. In addition, the recurrent tumor in the o-rMETase-treated group tended to be smaller than those in the untreated control. No side effects, including body weight loss were observed in the o-rMETase-treated group. The present study suggests that adjuvant o-rMETase might be tolerable for long periods. Future studies will determine whether treatment with o-rMETase for 3 weeks or more will result in better control of lung metastasis and extend survival.

Methionine restriction targets the methionine addiction of cancer cells (27, 28). We discovered methionine addiction in cancer cells almost 50 years ago (1-5, 29-32), which was recently claimed as novel (33, 34). rMETase can be used clinically as an effective oral supplement (35). o-rMETase is very effective for methionine depletion in the plasma of patients (35) and mice (10, 13, 36), and has many benefits, especially the lack of immunological reactions, compared to injected rMETase (37).

Our previous studies showed that the efficacy of o-rMETase was greater when combined with chemotherapy drugs (10-16), a concept we demonstrated in 1986 (38). In the present study, adjuvant o-rMETase for 2 weeks was possibly not sufficient to totally inhibit micrometastasis. The present study was a proof of concept that o-rMETase can inhibit lung metastasis in aggressive breast cancer in the adjuvant setting. Therefore, we plan a future study where adjuvant chemotherapy will be combined with o-rMETase.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Bar graphs showing relative body weight on day 22. Error bars:±SD.

In conclusion, adjuvant o-rMETase inhibited local recurrence and lung metastasis after primary tumor resection without any side effects in a 4T1 murine breast cancer orthotopic syngeneic model. The results of the present study suggest the clinical potential of o-rMETase for aggressive breast cancers in the adjuvant setting.

Acknowledgements

This paper is dedicated to the memory of A. R. Moossa, M.D., Sun Lee, M.D., Professor Li Jiaxi, and Masaki Kitajima, M.D.

Footnotes

  • Authors' Contributions

    Conception and design: NS and RMH. Acquisition of data: NS and KH. Analysis and interpretation of data: NS, KH, QH, JY, YS, HN, KK, MB, MU, and RMH. Writing, review, and/or revision of the manuscript: NS, MU, and RMH.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors declare that there are no potential conflicts of interest. AntiCancer, Inc. uses 4T1 cell syngeneic models for contract research. QH is an employee of AntiCancer, Inc. NS, KH, JY, YS, HN, and RMH are or were unsalaried associates of AntiCancer, Inc.

  • Received June 26, 2020.
  • Revision received July 14, 2020.
  • Accepted July 15, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Hoffman RM,
    2. Erbe RW
    : High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci USA 73(5): 1523-1527, 1976. PMID: 179090. DOI: 10.1073/pnas.73.5.1523
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Hoffman RM,
    2. Jacobsen SJ,
    3. Erbe RW
    : Reversion to methionine independence in simian virus 40-transformed human and malignant rat fibroblasts is associated with altered ploidy and altered properties of transformation. Proc Natl Acad Sci USA 76(3): 1313-1317, 1979. PMID: 220612. DOI: 10.1073/pnas.76.3.1313
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Stern PH,
    2. Hoffman RM
    : Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro 20(8): 663-670, 1984. PMID: 6500606. DOI: 10.1007/BF02619617
    OpenUrlPubMed
    1. Stern PH,
    2. Wallace CD,
    3. Hoffman RM
    : Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 119(1): 29-34, 1984. PMID: 6707100. DOI: 10.1002/jcp.1041190106
    OpenUrlCrossRefPubMed
  4. ↵
    1. Coalson DW,
    2. Mecham JO,
    3. Stern PH,
    4. Hoffman RM
    : Reduced availability of endogenously synthesized methionine for S-adenosylmethionine formation in methionine-dependent cancer cells. Proc Natl Acad Sci USA 79(14): 4248-4251, 1982. PMID: 6289297. DOI: 10.1073/pnas.79.14.4248
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Stern PH,
    2. Mecham JO,
    3. Wallace CD,
    4. Hoffman RM
    : Reduced free-methionine in methionine-dependent sv40-transformed human fibroblasts synthesizing apparently normal amounts of methionine. J Cell Physiol 117(1): 9-14, 1983. PMID: 6311851. DOI: 10.1002/jcp.1041170103
    OpenUrlCrossRefPubMed
  6. ↵
    1. Kaiser P
    : Methionine dependence of cancer. Biomolecules 10(4), 2020. PMID: 32276408. DOI: 10.3390/biom10040568
  7. ↵
    1. Tan Y,
    2. Xu M,
    3. Hoffman RM
    : Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells in vitro. Anticancer Res 30(4): 1041-1046, 2010. PMID: 20530407.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Tan Y,
    2. Xu M,
    3. Tan X,
    4. Tan X,
    5. Wang X,
    6. Saikawa Y,
    7. Nagahama T,
    8. Sun X,
    9. Lenz M,
    10. Hoffman RM
    : Overexpression and large-scale production of recombinant l-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy. Protein Expr Purif 9(2): 233-245, 1997. PMID: 9056489. DOI: 10.1006/prep.1996.0700
    OpenUrlCrossRefPubMed
  9. ↵
    1. Kawaguchi K,
    2. Han Q,
    3. Li S,
    4. Tan Y,
    5. Igarashi K,
    6. Kiyuna T,
    7. Miyake K,
    8. Miyake M,
    9. Chmielowski B,
    10. Nelson SD,
    11. Russell TA,
    12. Dry SM,
    13. Li Y,
    14. Singh AS,
    15. Eckardt MA,
    16. Unno M,
    17. Eilber FC,
    18. Hoffman RM
    : Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600e mutant melanoma: Implications for chronic clinical cancer therapy and prevention. Cell Cycle 17(3): 356-361, 2018. PMID: 29187018. DOI: 10.1080/15384101.2017.1405195
    OpenUrl
    1. Kawaguchi K,
    2. Miyake K,
    3. Han Q,
    4. Li S,
    5. Tan Y,
    6. Igarashi K,
    7. Kiyuna T,
    8. Miyake M,
    9. Higuchi T,
    10. Oshiro H,
    11. Zhang Z,
    12. Razmjooei S,
    13. Wangsiricharoen S,
    14. Bouvet M,
    15. Singh SR,
    16. Unno M,
    17. Hoffman RM
    : Oral recombinant methioninase (o-rMETase) is superior to injectable rmetase and overcomes acquired gemcitabine resistance in pancreatic cancer. Cancer Lett 432: 251-259, 2018. PMID: 29928962. DOI: 10.1016/j.canlet.2018.06.016
    OpenUrl
    1. Higuchi T,
    2. Kawaguchi K,
    3. Miyake K,
    4. Han Q,
    5. Tan Y,
    6. Oshiro H,
    7. Sugisawa N,
    8. Zhang Z,
    9. Razmjooei S,
    10. Yamamoto N,
    11. Hayashi K,
    12. Kimura H,
    13. Miwa S,
    14. Igarashi K,
    15. Chawla SP,
    16. Singh AS,
    17. Eilber FC,
    18. Singh SR,
    19. Tsuchiya H,
    20. Hoffman RM
    : Oral recombinant methioninase combined with caffeine and doxorubicin induced regression of a doxorubicin-resistant synovial sarcoma in a PDOX mouse model. Anticancer Res 38(10): 5639-5644, 2018. PMID: 30275182. DOI: 10.21873/anticanres.12899
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Park JH,
    2. Zhao M,
    3. Han Q,
    4. Sun Y,
    5. Higuchi T,
    6. Sugisawa N,
    7. Yamamoto J,
    8. Singh SR,
    9. Clary B,
    10. Bouvet M,
    11. Hoffman RM
    : Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model. Biochem Biophys Res Commun 518(2): 306-310, 2019. PMID: 31421825. DOI: 10.1016/j.bbrc.2019.08.051
    OpenUrl
    1. Oshiro H,
    2. Tome Y,
    3. Kiyuna T,
    4. Yoon SN,
    5. Lwin TM,
    6. Han Q,
    7. Tan Y,
    8. Miyake K,
    9. Higuchi T,
    10. Sugisawa N,
    11. Katsuya Y,
    12. Park JH,
    13. Zang Z,
    14. Razmjooei S,
    15. Bouvet M,
    16. Clary B,
    17. Singh SR,
    18. Kanaya F,
    19. Nishida K,
    20. Hoffman RM
    : Oral recombinant methioninase overcomes colorectal-cancer liver metastasis resistance to the combination of 5-fluorouracil and oxaliplatinum in a patient-derived orthotopic xenograft mouse model. Anticancer Res 39(9): 4667-4671, 2019. PMID: 31519565. DOI: 10.21873/anticanres.13648
    OpenUrlAbstract/FREE Full Text
    1. Higuchi T,
    2. Sugisawa N,
    3. Yamamoto J,
    4. Oshiro H,
    5. Han Q,
    6. Yamamoto N,
    7. Hayashi K,
    8. Kimura H,
    9. Miwa S,
    10. Igarashi K,
    11. Tan Y,
    12. Kuchipudi S,
    13. Bouvet M,
    14. Singh SR,
    15. Tsuchiya H,
    16. Hoffman RM
    : The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. Cancer Chemother Pharmacol 85(2): 285-291, 2020. PMID: 31705268. DOI: 10.1007/s00280-019-03986-0
    OpenUrl
  11. ↵
    1. Higuchi T,
    2. Han Q,
    3. Miyake K,
    4. Oshiro H,
    5. Sugisawa N,
    6. Tan Y,
    7. Yamamoto N,
    8. Hayashi K,
    9. Kimura H,
    10. Miwa S,
    11. Igarashi K,
    12. Bouvet M,
    13. Singh SR,
    14. Tsuchiya H,
    15. Hoffman RM
    : Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. Biochem Biophys Res Commun 523(1): 135-139, 2020. PMID: 31839218. DOI: 10.1016/j.bbrc.2019.12.024
    OpenUrl
  12. ↵
    1. Early Breast Cancer Trialists' Collaborative Group
    : Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365(9472): 1687-1717, 2005. PMID: 15894097. DOI: 10.1016/S0140-6736(05)66544-0
    OpenUrlCrossRefPubMed
  13. ↵
    1. Cortazar P,
    2. Zhang L,
    3. Untch M,
    4. Mehta K,
    5. Costantino JP,
    6. Wolmark N,
    7. Bonnefoi H,
    8. Cameron D,
    9. Gianni L,
    10. Valagussa P,
    11. Swain SM,
    12. Prowell T,
    13. Loibl S,
    14. Wickerham DL,
    15. Bogaerts J,
    16. Baselga J,
    17. Perou C,
    18. Blumenthal G,
    19. Blohmer J,
    20. Mamounas EP,
    21. Bergh J,
    22. Semiglazov V,
    23. Justice R,
    24. Eidtmann H,
    25. Paik S,
    26. Piccart M,
    27. Sridhara R,
    28. Fasching PA,
    29. Slaets L,
    30. Tang S,
    31. Gerber B,
    32. Geyer CE Jr..,
    33. Pazdur R,
    34. Ditsch N,
    35. Rastogi P,
    36. Eiermann W,
    37. von Minckwitz G
    : Pathological complete response and long-term clinical benefit in breast cancer: The ctneobc pooled analysis. Lancet 384(9938): 164-172, 2014. PMID: 24529560. DOI: 10.1016/S0140-6736(13)62422-8
    OpenUrlCrossRefPubMed
  14. ↵
    1. Early Breast Cancer Trialists' Collaborative G,
    2. Davies C,
    3. Godwin J,
    4. Gray R,
    5. Clarke M,
    6. Cutter D,
    7. Darby S,
    8. McGale P,
    9. Pan HC,
    10. Taylor C,
    11. Wang YC,
    12. Dowsett M,
    13. Ingle J,
    14. Peto R
    : Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378(9793): 771-784, 2011. PMID: 21802721. DOI: 10.1016/S0140-6736(11)60993-8
    OpenUrlCrossRefPubMed
  15. ↵
    1. Early Breast Cancer Trialists' Collaborative Group
    : Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet 386(10001): 1341-1352, 2015. PMID: 26211827. DOI: 10.1016/S0140-6736(15)61074-1
    OpenUrlCrossRefPubMed
  16. ↵
    1. Aslakson CJ,
    2. Miller FR
    : Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6): 1399-1405, 1992. PMID: 1540948.
    OpenUrlAbstract/FREE Full Text
    1. Lelekakis M,
    2. Moseley JM,
    3. Martin TJ,
    4. Hards D,
    5. Williams E,
    6. Ho P,
    7. Lowen D,
    8. Javni J,
    9. Miller FR,
    10. Slavin J,
    11. Anderson RL
    : A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17(2): 163-170, 1999. PMID: 10411109. DOI: 10.1023/a:1006689719505
    OpenUrlCrossRefPubMed
    1. Ouzounova M,
    2. Lee E,
    3. Piranlioglu R,
    4. El Andaloussi A,
    5. Kolhe R,
    6. Demirci MF,
    7. Marasco D,
    8. Asm I,
    9. Chadli A,
    10. Hassan KA,
    11. Thangaraju M,
    12. Zhou G,
    13. Arbab AS,
    14. Cowell JK,
    15. Korkaya H
    : Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat Commun 8: 14979, 2017. PMID: 28382931. DOI: 10.1038/ncomms14979
    OpenUrlCrossRef
  17. ↵
    1. Zhang Y,
    2. Zhang N,
    3. Hoffman RM,
    4. Zhao M
    : Surgically-induced multi-organ metastasis in an orthotopic syngeneic imageable model of 4T1 murine breast cancer. Anticancer Res 35(9): 4641-4646, 2015. PMID: 26254353.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Pinkas J,
    2. Martin SS,
    3. Leder P
    : Bcl-2-mediated cell survival promotes metastasis of EpH4 betaMEKDD mammary epithelial cells. Mol Cancer Res 2(10): 551-556, 2004. PMID: 15498929.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Yang M,
    2. Reynoso J,
    3. Bouvet M,
    4. Hoffman RM
    : A transgenic red fluorescent protein-expressing nude mouse for color-coded imaging of the tumor microenvironment. J Cell Biochem 106(2): 279-284, 2009. PMID: 19097136. DOI: 10.1002/jcb.21999
    OpenUrlCrossRefPubMed
  20. ↵
    1. Igarashi K,
    2. Kawaguchi K,
    3. Li S,
    4. Han Q,
    5. Tan Y,
    6. Murakami T,
    7. Kiyuna T,
    8. Miyake K,
    9. Miyake M,
    10. Singh AS,
    11. Eckardt MA,
    12. Nelson SD,
    13. Russell TA,
    14. Dry SM,
    15. Li Y,
    16. Yamamoto N,
    17. Hayashi K,
    18. Kimura H,
    19. Miwa S,
    20. Tsuchiya H,
    21. Singh SR,
    22. Eilber FC,
    23. Hoffman RM
    : Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. Cancer Lett 417: 168-173, 2018. PMID: 29306021. DOI: 10.1016/j.canlet.2017.12.028
    OpenUrl
  21. ↵
    1. Hoffman RM
    : Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: A 40-year odyssey. Expert Opin Biol Ther 15(1): 21-31, 2015. PMID: 25439528. DOI: 10.1517/14712598.2015.963050
    OpenUrl
  22. ↵
    1. Hoffman RM,
    2. Jacobsen SJ
    : Reversible growth arrest in simian virus 40-transformed human fibroblasts. Proc Natl Acad Sci USA 77(12): 7306-7310, 1980. PMID: 6261250. DOI: 10.1073/pnas.77.12.7306
    OpenUrlAbstract/FREE Full Text
    1. Hoshiya Y,
    2. Guo H,
    3. Kubota T,
    4. Inada T,
    5. Asanuma F,
    6. Yamada Y,
    7. Koh J,
    8. Kitajima M,
    9. Hoffman RM
    : Human tumors are methionine dependent in vivo. Anticancer Res 15(3): 717-718, 1995. PMID: 7645948.
    OpenUrlPubMed
    1. Hoshiya Y,
    2. Kubota T,
    3. Matsuzaki SW,
    4. Kitajima M,
    5. Hoffman RM
    : Methionine starvation modulates the efficacy of cisplatin on human breast cancer in nude mice. Anticancer Res 16(6B): 3515-3517, 1996. PMID: 9042214.
    OpenUrlPubMed
  23. ↵
    1. Hoshiya Y,
    2. Kubota T,
    3. Inada T,
    4. Kitajima M,
    5. Hoffman RM
    : Methionine-depletion modulates the efficacy of 5-fluorouracil in human gastric cancer in nude mice. Anticancer Res 17(6D): 4371-4375, 1997. PMID: 9494535.
    OpenUrlPubMed
  24. ↵
    1. Wang Z,
    2. Yip LY,
    3. Lee JHJ,
    4. Wu Z,
    5. Chew HY,
    6. Chong PKW,
    7. Teo CC,
    8. Ang HY,
    9. Peh KLE,
    10. Yuan J,
    11. Ma S,
    12. Choo LSK,
    13. Basri N,
    14. Jiang X,
    15. Yu Q,
    16. Hillmer AM,
    17. Lim WT,
    18. Lim TKH,
    19. Takano A,
    20. Tan EH,
    21. Tan DSW,
    22. Ho YS,
    23. Lim B,
    24. Tam WL
    : Methionine is a metabolic dependency of tumor-initiating cells. Nat Med 25(5): 825-837, 2019. PMID: 31061538. DOI: 10.1038/s41591-019-0423-5
    OpenUrlCrossRef
  25. ↵
    1. Gao X,
    2. Sanderson SM,
    3. Dai Z,
    4. Reid MA,
    5. Cooper DE,
    6. Lu M,
    7. Richie JP Jr..,
    8. Ciccarella A,
    9. Calcagnotto A,
    10. Mikhael PG,
    11. Mentch SJ,
    12. Liu J,
    13. Ables G,
    14. Kirsch DG,
    15. Hsu DS,
    16. Nichenametla SN,
    17. Locasale JW
    : Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature 572(7769): 397-401, 2019. PMID: 31367041. DOI: 10.1038/s41586-019-1437-3
    OpenUrlCrossRefPubMed
  26. ↵
    1. Han Q,
    2. Tan Y,
    3. Hoffman RM
    : Oral dosing of recombinant methioninase is associated with a 70% drop in PSA in a patient with bone-metastatic prostate cancer and 50% reduction in circulating methionine in a high-stage ovarian cancer patient. Anticancer Res 40(5): 2813-2819, 2020. PMID: 32366428. DOI: 10.21873/anticanres.14254
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Tashiro Y,
    2. Han Q,
    3. Tan Y,
    4. Sugisawa N,
    5. Yamamoto J,
    6. Nishino H,
    7. Inubushi S,
    8. Higuchi T,
    9. Aoki T,
    10. Murakami M,
    11. Hoffman RM
    : Oral recombinant methioninase prevents obesity in mice on a high-fat diet. In Vivo 34(2): 489-494, 2020. PMID: 32111745. DOI: 10.21873/invivo.11799
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Yang Z,
    2. Wang J,
    3. Lu Q,
    4. Xu J,
    5. Kobayashi Y,
    6. Takakura T,
    7. Takimoto A,
    8. Yoshioka T,
    9. Lian C,
    10. Chen C,
    11. Zhang D,
    12. Zhang Y,
    13. Li S,
    14. Sun X,
    15. Tan Y,
    16. Yagi S,
    17. Frenkel EP,
    18. Hoffman RM
    : PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 64(18): 6673-6678, 2004. PMID: 15374983. DOI: 10.1158/0008-5472.CAN-04-1822
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Stern PH,
    2. Hoffman RM
    : Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 76(4): 629-639, 1986. PMID: 3457200. DOI: 10.1093/jnci/76.4.629
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (9)
Anticancer Research
Vol. 40, Issue 9
September 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model
NORIHIKO SUGISAWA, KAZUYUKI HAMADA, QINGHONG HAN, JUN YAMAMOTO, YU SUN, HIROTO NISHINO, KEI KAWAGUCHI, MICHAEL BOUVET, MICHIAKI UNNO, ROBERT M. HOFFMAN
Anticancer Research Sep 2020, 40 (9) 4869-4874; DOI: 10.21873/anticanres.14489

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model
NORIHIKO SUGISAWA, KAZUYUKI HAMADA, QINGHONG HAN, JUN YAMAMOTO, YU SUN, HIROTO NISHINO, KEI KAWAGUCHI, MICHAEL BOUVET, MICHIAKI UNNO, ROBERT M. HOFFMAN
Anticancer Research Sep 2020, 40 (9) 4869-4874; DOI: 10.21873/anticanres.14489
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Engineered Methioninase-expressing Tumor-targeting Salmonella typhimurium A1-R Inhibits Syngeneic-Cancer Mouse Models by Depleting Tumor Methionine
  • Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin
  • Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet
  • [11C] Methionine-PET Imaging as a Cancer Biomarker for Methionine Addiction and Sensitivity to Methionine-restriction-based Combination Chemotherapy
  • Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction
  • Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model
  • Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model
  • Google Scholar

More in this TOC Section

  • Apigenin-induced Apoptosis in Lung Adenocarcinoma A549 Cells: Involvement in IFNA2, TNF, and SPON2 With Different Time Points
  • Study of the Cytotoxic and Antitumor Effect of L-lysine-α-oxidase from Trichoderma harzianum Rifai
  • Damnacanthal Suppresses TCF4 Expression in Colorectal Cancer Cells
Show more Experimental Studies

Similar Articles

Keywords

  • breast cancer
  • surgical resection
  • recurrence
  • methionine restriction
  • recombinant methioninase
  • lung metastasis
  • inhibition
  • adjuvant therapy
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire